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Summary
Current treatment for type I diabetes includes delivery of insulin via injection or pump, which
is highly invasive and expensive. The production of chloroplast-derived proinsulin should
reduce cost and facilitate oral delivery. Therefore, tobacco and lettuce chloroplasts were
transformed with the cholera toxin B subunit fused with human proinsulin (A, B, C peptides)
containing three furin cleavage sites (CTB-PFx3). Transplastomic lines were confirmed for sitespecific integration of transgene and homoplasmy. Old tobacco leaves accumulated proinsulin
up to 47% of total leaf protein (TLP). Old lettuce leaves accumulated proinsulin up to 53%
TLP. Accumulation was so stable that up to 40% proinsulin in TLP was observed even in
senescent and dried lettuce leaves, facilitating their processing and storage in the field. Based
on the yield of only monomers and dimers of proinsulin (3 mg ⁄ g leaf, a significant underestimation), with a 50% loss of protein during the purification process, one acre of tobacco
could yield up to 20 million daily doses of insulin per year. Proinsulin from tobacco leaves was
purified up to 98% using metal affinity chromatography without any His-tag. Furin protease
cleaved insulin peptides in vitro. Oral delivery of unprocessed proinsulin bioencapsulated in
plant cells or injectable delivery into mice showed reduction in blood glucose levels similar to
processed commercial insulin. C-peptide should aid in long-term treatment of diabetic complications including stimulation of nerve and renal functions. Hyper-expression of functional proinsulin and exceptional stability in dehydrated leaves offer a low-cost platform for oral and
injectable delivery of cleavable proinsulin.

Introduction
Type I diabetes is an autoimmune disorder that results from the
T-cells of the body’s immune system attacking the b-cells of the
islets of Langerhans in the pancreas. It represents 5%–10% of
all diabetes cases. However, type 1 diabetes accounts for over
90% of diabetes cases in children (Giannini et al., 2009). As of
2007, it was reported that diabetes was the seventh leading
cause of death in the USA. The main aetiology of type I diabetes is a drop in insulin levels due to the destruction of the insulin-producing pancreatic b-cells, and therefore this leads to
abnormally high blood glucose levels. This can lead to symptoms of the disease such as frequent urination, extreme hunger
and thirst, weight loss, fatigue and irritability. However, over
time, sustained hyperglycaemia leads to a number of other
more serious complications such as heart disease, high blood
pressure, kidney disease and nervous system disease (CDC,
2008). It is these complications from diabetes that ultimately
lead to death if left untreated.
Estimated annual costs in 2007 for diabetes care and other
indirect costs for the United States alone totalled $174 billion
with roughly $116 billion in excess medical expenditures comprised of $27 billion going to direct care, $58 billion to treat
diabetic complications and $31 billion in excess general medical
costs. It is estimated that approximately $1 out of every $10
health care dollars is attributed to diabetes (American Diabetes
Association, 2008). As the prevalence of diabetes worldwide

continues to increase, these costs are projected to be between
$213 and $396 billion by the year 2025 (Giannini et al., 2009).
In many developing countries, the annual cost for insulin
exceeds 50% of the average annual income. In developed
countries, the cost of insulin alone is around $100 per month
(Raab et al., 2004). Therefore, there is a great need to reduce
the economic burden on people dealing with this disease.
Insulin is a 51 amino acid peptide hormone with a molecular
weight of 5.8 kDa which is derived from its precursor, proinsulin. Proinsulin is produced in the pancreas as a 110 amino acid
polypeptide containing a 24 amino acid signal sequence and
the 86 amino acid proinsulin molecule consisting of the B-chain
(30 aa), C peptide (34 aa) and A-chain (21 aa). During insulin
biosynthesis in the pancreas, the C-peptide is cleaved off via
the action of prohormone convertases 2 and 3 at the Bchain ⁄ C-peptide and C-peptide ⁄ A-chain junctions, respectively,
and insulin (51 aa) is formed via disulphide bonds between the
A- and B-chains (Steiner, 1998; Shaw et al., 2002). Commercial
insulin production first began in 1922 and consisted of insulin
harvested from bovine or porcine pancreas. Thirty years later,
the amino acid sequence of human insulin was determined,
and by the 1970s scientists were able to recreate the sequence
in order to produce recombinant human insulin. This eliminated
previous problems with adverse immune reactions from animalderived insulin. Recently, insulin analogues such as insulin lispro
and insulin aspart have been manufactured to contain amino
acid alterations that increase absorption time (Levinson, 2003).
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Commercial preparations of insulin are produced mainly in Escherichia coli (Swartz, 2001) or yeast (Kjeldsen, 2000) as fusion
proteins. In E. coli, the A-chain and the B-chain genes are introduced into two separate colonies, and the fusion peptides are
produced individually. Then, the two chains are mixed together
and joined by disulphide bonding. The folded insulin is subsequently purified. Alternatively, insulin is produced from the proinsulin gene in yeast. However, C-peptide is removed from the
final product.
Although insulin is predominantly made in bacteria or yeast
for commercial production, there has been further research
focusing on other methods for producing insulin including
expression in plants. Earlier attempts at insulin expression in
plant tissues have focused mainly on treating the autoimmune
aspect of the disease by induction of oral tolerance. Both CTBinsulin produced in potato tubers (Arakawa et al., 1998) and
cholera toxin B subunit (CTB) fused with three copies of the
insulin B-chain expressed in the tobacco nuclear genome (Li
et al., 2006) showed expression levels of only 0.1% of total soluble protein. A recent review article reports expression of various proinsulin constructs with or without C-peptide in
Arabidopsis seeds that accumulated up to 1% total seed protein (Boothe et al., 2010). However, there is no reference for
oral delivery of insulin expressed in plant cells, and there is a
need to increase expression levels in large biomass crops in
order to further advance this concept. Therefore, we have
expressed in plant chloroplasts a CTB-proinsulin fusion protein
containing three furin cleavage sites, one of which is located at
the point of fusion, and two other sites flank either end of the
C-peptide (CTB-PFx3). The vector DNA sequence can be seen in
figure S1.
Chloroplast genetic engineering in plants offers several
advantages over nuclear transformation. Some of these advantages include higher copy number and expression levels of the
transgene. Each chloroplast may contain up to 100 genomes,
while each plant cell may contain up to 100 chloroplasts.
Therefore, each plant cell may contain as many as 10 000 chloroplast genomes which results in high expression levels of proteins expressed via the chloroplast genome. Expression levels of
up to 70% total soluble protein (Oey et al., 2009) and 72%
total leaf protein (Ruhlman et al., 2010) of biopharmaceutical
proteins have been reported in transgenic chloroplasts, which
are the highest levels reported in published literature in this
field. Chloroplasts offer gene containment through maternal
inheritance, as the chloroplast genome is not transferred
through pollen unlike nuclear genomic DNA (Daniell, 2007).
The chloroplast vectors are designed with flanking regions that
are homologous to the chloroplast genome, and this prevents
unwanted positional effects or gene silencing. Furthermore,
chloroplasts have the ability to transcribe polycistronic RNA
(Quesada-Vargas et al., 2005) and can perform the correct processing of eukaryotic proteins including the ability to carry out
post-translational modifications such as disulphide bonding,
assembly of multimers and lipid modifications (Arlen et al.,
2007, 2008; Bally et al., 2008; Daniell et al., 2009a,b; Lee
et al., in press). Finally, plants offer the benefit of low-cost production of proteins and the protection of antigen via bioencapsulation (Limaye et al., 2006; Arlen et al., 2008; Daniell et al.,
2009a; Davoodi-Semiromi et al., 2009; Verma et al., 2010).
These advantages make the chloroplast ideal for production of
biopharmaceutical proteins and vaccines as well as an ideal
vehicle for oral delivery. Ideally, expression of insulin in chlorop-

lasts should provide a low-cost means to produce biologically
functional insulin, which could be administered through both
the injectable and oral delivery methods. Correct processing of
proinsulin involves production of three intramolecular disulphide
bonds, whereas CTB is required for assembly into pentamers in
order to be successfully absorbed into the circulation via the
GM1 receptors on the gut mucosa (Limaye et al., 2006). Chloroplasts are capable of performing necessary post-translational
modifications, which are essential for the functionality of CTBPFx3 (Limaye et al., 2006; Arlen et al., 2008; Bally et al., 2008;
Daniell et al., 2009a; Davoodi-Semiromi et al., 2009; Verma
et al., 2010; Lee et al., in press). Efficient transformation of
plastids of edible crops was recently achieved (Ruhlman et al.,
2010), further facilitating the oral delivery of therapeutic proteins.
The production of chloroplast-derived, orally deliverable functional insulin should provide many benefits including a lower
cost of production and the possibility of delivering the C-peptide, which is currently lacking in commercially available insulin.
This is of great importance because type 1 diabetic patients fail
to produce C-peptide, an essential molecule that once was
thought to be biologically inactive. C-peptide is located in
between the B-chain and A-chain of the proinsulin molecule.
Only recently, C-peptide has been shown to function independently of insulin. C-peptide acts via G-protein activation, which
signals the cell to open Ca2+ channels allowing for an influx of
cellular Ca2+. This leads to stimulation of eNOS, Na+, K+-ATPase
and the MAP kinase pathway (Wahren, 2004). This action of
C-peptide is thought to be the mechanism behind the beneficial effects seen upon restoration of C-peptide levels in type 1
diabetic animals and humans (Johansson et al., 2000; Sima and
Li, 2005; Hills and Brunskill, 2009). Stimulation of the activities
of Na+, K+-ATPase and endothelial nitric oxide synthase (eNOS)
is essential for nerve function (Ekberg et al., 2003; Wahren
et al., 2007), and the stimulation of Na+, K+-ATPase also leads
to correction of renal structure and function (Rebsomen et al.,
2008).
Furin is an endoprotease present in the constitutive secretory
pathway and cell surface of virtually all cells (Taylor et al.,
2003). The consensus sequence for furin cleavage is the C-terminal arginine in the amino acid sequence Arg-X-Lys ⁄ Arg-Arg
(Thomas, 2002). The introduction of furin consensus sequences
at the B-chain ⁄ C-peptide and the C-peptide ⁄ A-chain has been
demonstrated to increase the processing of proinsulin to mature
insulin in a wide variety of non-neuroendocrine cells, including
fibroblasts, myoblasts, epithelial cells and lymphocytes (Groskreutz et al., 1994; Fujimoto et al., 2005; Tatake et al., 2007). In
contrast, native proinsulin is processed in the pancreatic b-cells
via prohormone convertases PC2 ⁄ PC3. Non-neuroendocrine
cells therefore do not possess the ability to process proinsulin
into mature insulin. This processing is necessary for function of
insulin, so addition of furin cleavage sites is necessary to facilitate processing in the gut. Although several different furin
cleavage sites have been engineered, there seems to be the
best processing (87%) of human proinsulin to unmodified
mature human insulin using the Arginine Arginine Lysine Arginine (RRKR) furin cleavage sequence in adult fibroblasts (Shaw
et al., 2002). Therefore, this sequence was engineered into proinsulin. Tobacco was used as a model system to quantify the
production and facilitate the purification of CTB-PFx3 as well as
monitor its functionality. Subsequentially, CTB-PFx3 was produced in lettuce for oral delivery studies.
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Results

After 4–6 weeks, green shoots appeared and were subjected to
three rounds of selection. Homoplasmy was confirmed by
Southern blots. Transformed and untransformed tobacco DNA
was digested with AflIII and probed with a 0.81-kb sequence
complimentary to the trnI ⁄ trnA region of the native chloroplast
genome. This produced a 4.2-kb fragment in the untransformed tobacco (Figure 2a) and a 6.4-kb fragment in the transplastomic tobacco (Figure 2b). Both transplastomic lines A and
B showed only one hybridizing fragment of 6.4-kb size and did
not show a fragment of the same size as the untransformed
plant, indicating that all the chloroplast genomes had integrated
the foreign gene and confirmed homoplasmy (Figure 2c). Similarly, transformed and untransformed lettuce DNA was digested
with BglII which produced a 3.75-kb fragment in the untransformed lettuce (Figure 3a) and a 6.3-kb fragment in the transplastomic lettuce (Figure 3b). Only the 6.3-kb band was present
in all transplastomic lines tested, confirming homoplasmy (Figure 3c).

Chloroplast vectors for expression of cleavable
proinsulin
The CTB-PFx3 gene construct was inserted into the pLD vector
as previously established by the Daniell laboratory (Verma and
Daniell, 2007; Verma et al., 2008) or the pLsLF vector (Ruhlman
et al., 2007, 2010) under the control of the light-regulated psbA
region located within the 5¢ UTR. Both vectors contain the aadA
gene that confers resistance to spectinomycin and are driven by
the upstream prrn promoter. Chloroplast vectors include native
tobacco or lettuce DNA flanking regions (trnI ⁄ trnA) in order to
facilitate homologous recombination. The CTB gene was separated from the proinsulin gene via a Glycine–Proline–Glycine–
Proline (GPGP) hinge to avoid steric hindrance, followed by a furin cleavage site (RRKR) to enable removal of the CTB following
delivery. Two additional furin cleavage sites were engineered at
the B-chain ⁄ C-peptide and the C-peptide ⁄ A-chain junctions,
replacing the native PC2 and PC3 cleavage sites as previously
described (Shaw et al., 2002). The location of engineered cleavage sites and disulphide bonds are compared with native proinsulin in Figure 1. The location of CTB fusion is also shown.

Detection and quantification of cleavable proinsulin
Coomassie staining and immunoblotting were used to determine whether the transgenic plants were expressing CTB-PFx3.
Transplastomic and untransformed young, mature and old
leaves were ground to a fine powder in liquid nitrogen, and
protein was extracted with the addition of 300–500 lL plant
extraction buffer. Young leaves are the new, light green, smaller leaves growing at the top of the plant. Mature leaves are

Chloroplast transformation and evaluation of
homoplasmy
Chloroplast vectors pLDutr-CTB-Fx3Pris and pLsLF-CTB-Fx3Pris
were bombarded into tobacco and lettuce leaves, respectively.
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Figure 1 Location of furin cleavage sites. N and C termini are indicated. (a) Native proinsulin. (9 kDa) (b) Proinsulin molecule was modified to include
furin cleavage sites and fused to cholera toxin B subunit (CTB). MW of CTB is 11 kDa. MW of modified CTB-proinsulin molecule is 22 kDa. Fusion proteins are expressed by the CTB-Fx3Pris coding region of the pLDutr-CTB-Fx3Pris or pLsLF-CTB-Fx3Pris chloroplast vector.
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tobacco plastome. Digestion with AflIII yields a 6.4-kb fragment. The 5¢UTR represents the light-regulated psbA promoter. (c) Southern analysis from T1
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large, dark green and grow towards the middle of the plant.
Old leaves are the bottom-most senescent leaves that are
beginning to turn brown. Samples were spun down, and the
resulting supernatant, pellet and homogenate fractions were
collected and run on a 12% SDS–PAGE gel (Figure 4a). A polypeptide was seen prominently at 22 kDa in the pellet and
homogenate fractions, but not in the supernatant, indicating
that the CTB-PFx3 accumulated in the form of insoluble inclusion bodies. Immunoblots were performed using anti-CTB antibody to further confirm transgene expression. Young, mature
and old homogenate samples were loaded in equal protein concentrations along with wild-type homogenate and recombinant
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CTB protein (Figure 4b). A prominent band at 22 kDa represents the monomer size of the CTB-PFx3, but it is clear that the
protein forms dimers, trimers, tetramers, pentamers and multimers of 44 kDa, 66 kDa, 88 kDa and 110 kDa sizes. Varying
dilutions of the CTB-PFx3 homogenate were loaded onto a
12% SDS–PAGE gel along with known concentrations of
recombinant CTB protein, and spot densitometry was performed in order to quantify expression levels (Figure 4c). Different concentrations of CTB were loaded onto the gel in order to
generate a standard curve (Figure 4d). CTB-PFx3 was expressed
in levels up to 47% in old leaves (Figure 4e) and as much as
2.92 mg ⁄ g leaf tissue (Figure 4f).
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Figure 4 Characterization of cholera toxin B subunit (CTB)-proinsulin expressed in tobacco chloroplasts. (a) Coomassie stain. M, marker; S, supernatant; P, pellet; H, homogenate; WT, untransformed plant. S and H: 30 lg per lane. P: 7.5 lg per lane. (b) Western blot probed with anti-CTB antibody
showing CTB-PFx3 expression of young, mature and old leaf total protein. 1 lg per lane. CTB: 100 ng CTB standard. Arrows represent the monomer,
dimer and trimer bands, respectively. (c) CTB-PFx3 total protein was loaded in varying concentrations and compared to known quantities of CTB standard protein using densitometry. Blot was probed using anti-CTB antibody. (d) Plot of integrated density values (IDV) for quantification of CTBPFx3
based on standard curve. Broken line shows data points. Solid line: trend line. (e) Per cent total protein for young, mature and old leaves based on
densitometry values. (f) Quantification of young, mature and old leaves in mg CTB-PFx3 per gram total leaf tissue.
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Figure 5 Characterization of cholera toxin B subunit (CTB)-proinsulin expressed in lettuce chloroplasts. (a) CTB-PFx3 total protein was loaded in varying
concentrations and compared to known quantities of CTB standard protein using densitometry. Blot was probed using anti-CTB antibody. (b) Plot of
integrated density values (IDV) for quantification of CTB-PFx3 based on standard curve. Broken line shows data points. Solid line: trend line. (c) Per cent
total protein for young, mature and old leaves based on densitometry values. (d) Quantification of young, mature and old leaves in mg CTBPFx3 per
gram total leaf tissue.

Transgenic lettuce plants were prepared in the same way as
tobacco, and varying dilutions of the samples were loaded onto
a 12% SDS–PAGE gel for spot densitometric analysis of protein
concentration (Figure 5a). Different concentrations of recombinant CTB protein were loaded onto the gel in order to create a
standard curve (Figure 5b). Of the four lines tested, CTB-PFx3
was found to account for up to 53% of the total leaf protein
(Figure 5c) and as much as 3.28 mg ⁄ g leaf tissue (Figure 5d).
The majority of expressed protein was found in the old leaves,
and expression levels were comparable to levels observed in
tobacco.
Additionally, owing to the high levels of expression observed
in old leaves, senescent and dried lettuce leaves were tested to
investigate stability of CTB-PFx3. Senescent leaves that were
completely brown and dry were harvested from transplastomic
lettuce plants, and protein was extracted as previously
described. Leaf homogenate ranging from 0.125 to 2 lg total
leaf protein was loaded on a 12% SDS–PAGE gel and probed
with CTB or insulin antibodies (Figure 6, a and b). High levels of
CTB-PFx3 expression, up to 39% total leaf protein, were
detected even in senescent lettuce leaf material, further demonstrating that owing to the insolubility of CTB-PFx3, it is highly
stable and protected from proteolytic degradation.

Solubilization and furin cleavage of proinsulin
To prepare the CTB-PFx3 for purification and cleavage assays, it
was feasible to remove this protein as inclusion bodies and convert into a soluble form. Previously, in our laboratory, insoluble
inclusion bodies of human serum albumin (HSA) expressed in
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Figure 6 Expression of cholera toxin B subunit (CTB)-proinsulin in dried
senescent lettuce leaves. (a) CTB-PFx3 total protein from dried leaf
homogenate was loaded in 1 or 2 lg concentrations along with varying
dilutions of CTB standard protein. Immunoblot was probed with antiCTB antibody. (b) CTB-PFx3 total protein from dried leaf homogenate
was loaded in 1 or 2 lg concentrations along with varying dilutions of
insulin standard protein (shown as multimers). Immunoblot was probed
with anti-insulin antibody.

tobacco chloroplasts were solubilized and successfully purified
(Fernandez-San Millan et al., 2003). Solubilization was achieved
using high quantities of guanidine hydrochloride (Gu-HCl) and
DTT. DTT was added to pellet resuspended in plant extraction
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buffer containing 6 M Gu-HCl. No CTB-PFx3 was found in the
supernatant fraction after extraction, and this protein was
entirely seen in the pellet fraction. Addition of 100 mM DTT
achieved some solubility, but addition of 200 or 300 mM DTT
achieved almost complete solubility of CTB-PFx3. Therefore,
300 mM DTT was used for all subsequent solubilizations. After
solubilization, the denatured protein was refolded in 20 mM
sodium phosphate pH 7.8 and 500 mM NaCl. To determine
whether the engineered cleavage sites were functional, a furin
cleavage assay was performed (Figure 7a). Upon addition of furin and immunoblot visualization with CTB antibody, it is seen
that the 22 kDa polypeptide representing the size of the CTBPFx3 monomer disappears, and a polypeptide is seen at
11 kDa representing CTB alone as well as a polypeptide at
14 kDa which most likely represents an incomplete cleavage
between CTB and proinsulin consisting of CTB fused to the Bchain of proinsulin, with cleavage occurring at the B-chain ⁄ C
peptide junction. The proinsulin 2–3 kDa cleavage products
were not detected by immunoblot with insulin antibody most
likely because of the small size of the protein. Silver stain was
then performed to visualize the 2–3 kDa products (Figure 7b).
In this gel, the monomer of CTB-PFx3 is seen to decrease after
addition of furin, and a large band appears at the 2–3 kDa size.
One large band is visualized because the A-chain, C peptide
and B-chain cleavage products of proinsulin are 2 kDa, 2.5 kDa
and 3 kDa, respectively, which are too close in size to be
resolved independently.

Purification and enrichment of proinsulin using nickel
affinity chromatography
Solubilized and dialysed plant extracts containing CTB-PFx3
were passed over a Ni-NTA column to facilitate purification.
Fractions were eluted and run on an SDS–PAGE gel and visualized by coomassie staining (Figure 8a). The 55-kDa Rubisco
large subunit is seen prominently in the wild-type sample. This
is typical as Rubisco is the most abundant protein in plants and
probably the most abundant protein on earth (Jensen, 2000).
The 22-kDa band of CTB-PFx3 is seen prominently in the control pellet (CP), but not in the control supernatant (CS), again

(a)

CTB

–F

+F

showing that the protein is in the form of inclusion bodies.
After solubilization and dialysis, CTB-PFx3 is detected in the dialysed supernatant fraction (DS). Approximately 30 mL of dialysed supernatant was passed over the Ni-NTA column. No
protein is seen to elute in the wash fractions (W1 and W2). The
two eluted fractions with the highest optical density (OD) at
280 nm were run on the gel. The 22 kDa polypeptide representing CTB-PFx3 is seen prominently along with Rubisco, but it
is seen that the contaminating protein bands are much less
abundant; therefore, total CTB-PFx3 protein content was purified and compared with the starting material.
Purification was repeated in order to achieve a greater level
of purity by removing Rubisco. In order to enhance purification,
old leaves were prepared in the same way as in the previous
purification as they contain less Rubisco, and samples were run
over a Ni-NTA column. After purification, additional Rubisco
was removed using sodium phytate precipitation (Krishnan and
Natarajan, 2009), and samples were loaded on an SDS–PAGE
gel for coomassie staining (Figure 8b).
The resultant purified fractions were loaded in equal quantity
onto an SDS–PAGE gel for immunoblot analysis along with the
dialysed supernatant, flow through and wash fractions. Blots
were probed with either anti-CTB antibody (Figure 8c) or antiinsulin antibody (Figure 8d). In both blots, the purified CTB-PFx3
is shown to be highly enriched compared to the dialysed supernatant. Additionally, the CTB-PFx3 monomer is enhanced,
which would provide the functional, cleavable proinsulin. Densitometric analysis showed that the original dialysed supernatant
contained 27% CTB-PFx3, whereas after the first purification,
this increased to an average of 57% purity (range determined
by densitometry to be between 42% and 72%), a nearly twofold increase. After the second step of purification followed by
sodium phytate precipitation, the sample was shown to be
about 87% pure (range determined by densitometry to be
between 75% and 98%), over a threefold increase from the
original dialysed supernatant and a 1.5-fold increase from the
first purification (Figure 8e). The starting concentration of the
CTB-PFx3 in the dialysed supernatant was 30 000 ng ⁄ mL
(0.03 mg ⁄ mL)
which
increased
to
320 000 ng ⁄ mL
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Figure 7 Furin cleavage assays. Samples were solubilized with 6 M Gu-HCl and 300 mM DTT and subsequently dialysed in 20 mM Na+ PO4) buffer with
500 mM NaCl before addition of Furin protease. (a) Furin digestion of CTB-PFx3. CTB, 100 ng CTB standard protein. –F, CTB-PFx3 before furin cleavage. +F, CTB-PFx3 after addition of furin. 1 lg per lane. (b) Silver stained gel after affinity purification of CTB-PFx3. Lane 1, precision plus ladder. Lane
2, Mark 12 low molecular weight ladder. Lane 3, purified CTB-PFx3 1 lg per lane. Lane 4, purified CTB-PFx3 after addition of furin. 1 lg per lane.
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Figure 8 Purification of cholera toxin B subunit (CTB)-proinsulin by affinity chromatography. (a) Coomassie stained gel. DS = dialysed supernatant;
FT = flow through; W1 = wash 1; W2 = wash 2; 2,3 = purified fractions; WT = untransformed plant material; CS = control supernatant; CP = control
pellet (b) Coomassie stained gel showing second purification of CTB-PFx3: Lane 1: Marker. Lane 2: control pellet (before purification). Lane 3: Purified
CTB-PFx3, Lane 4: Purified CTB-PFx3 after phytate precipitation to remove Rubisco. Lane 5: Control supernatant. All 10 lg load. (c) 1 lg of purified
CTB-PFx3 samples were loaded using CTB primary antibody. DS = dialysed supernatant; FT = flow through; W1 = wash 1; W2 = wash 2; 2, 3 = purified fractions (d) 1 lg of purified CTB-PFx3 samples were loaded using insulin primary antibody. DS = dialysed supernatant; FT = flow through;
W1 = wash 1; W2 = wash 2; 2, 3 = purified fractions (e) Densitometry shows that after purification, CTB-PFx3 makes up 57% of the eluted fractions
after the first purification and 87% after the second purification as compared to 27% of the dialysed solubilized supernatant before passing over
the nickel column. (f) The concentration of CTB-PFx3 increases roughly 10-fold (320 000 ng ⁄ mL) after the first purification and 4.6-fold
(140 000 ng ⁄ mL) after the second purification over nickel column than the initial concentration of dialysed solubilized supernatant
(30 000 ng ⁄ mL).

(0.32 mg ⁄ mL)
after
the
first
purification
and
to
140 000 ng ⁄ mL (0.14 mg ⁄ mL) after the second purification
representing a total enrichment greater than 10-fold and 4.5fold, respectively (Figure 8f). The lower concentration in the second purification is most likely due to the fact that less total
sample volume was loaded onto the column resulting in a lower
concentration but achieving higher purity.

Functional evaluation of cleavable proinsulin
CTB-PFx3 purified from transplastomic tobacco as well as commercially produced purified insulin (Roche, Basel, Switzerland)
was injected into female C57BL ⁄ 6 mice along with PBS as a

negative control. Blood glucose measurements were made by
tail vein bleed before intraperitoneal (IP) injection and at 15-,
30-, 60-, 120- and 180-min time intervals. Another injection
was given after the 180-min time point, and blood glucose
measurements were again made at 15-, 30-, 60-, 120- and
180-min time points after the second injection. Blood glucose
levels were found to be significantly lower than PBS control in
all groups at the 120-min time point after the second injection
(Figure 9a), similar to commercial insulin.
Additionally, transplastomic lettuce and tobacco plants along
with untransformed lettuce were delivered to mice by oral
gavage. Commercially produced purified insulin was injected as
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Figure 9 Functional evaluation of cholera toxin B subunit (CTB)-proinsulin in mice delivered by injection or oral gavage. ANOVA (Dunnett’s multiple
comparison test) was performed on all groups of mice. (a) Mice were administered two intraperitoneal (IP) injections of PBS only (PBS), purified CTBPFx3 (Tg) or commercial Insulin (INS Comm.). Blood glucose levels were measured after the first 15 min and each hour (up to three hours) after each
injection. Blood glucose levels were statistically lower (**P < 0.01) 2 h after the second injection in all groups compared to the PBS only negative control. (b) Mice were administered two oral gavages of untransformed lettuce (WT), tobacco expressing CTB-PFx3 (Tg tobacco), lettuce expressing CTBPFx3 (Tg lettuce) or two IP injections of commercial Insulin (INS Comm.). Blood glucose levels were measured after the first 15 min and each hour (up
to three hours) after each injection. Blood glucose levels were statistically lower (**P < 0.01; ***P < 0.001) 2 h after the second injection in all groups
compared to the untransformed (WT) control.

a control. Blood glucose measurements were taken by tail vein
bleed before gavage or injection and at 15-, 30-, 60-, 120- and
180-min time intervals. Another dose was given after the 180min time point, and blood glucose measurements were again
taken at 15-, 30-, 60- and 120-min time points after the second
dose. Blood glucose levels were found to be significantly lower
than untransformed control in all groups at the 120-min time
point after the second injection (Figure 9b). Food pellets were
removed from cages for the duration of both studies.

Discussion
Existing treatments for type 1 diabetes are painful, costly, and
currently available insulin does not include the C-peptide. Here,
we have expressed CTB-proinsulin with three furin cleavage
sites in both tobacco and lettuce chloroplasts in order to produce insulin that may be processed in most cells in the body.
This will significantly reduce the cost of production, as well as
facilitate the possibility of delivering the C-peptide, which
should aid in the treatment of diabetic complications. One acre
of farm land can yield about 40 metric tons of tobacco with
three harvests (Arlen et al., 2007) or 11 metric tons of lettuce
biomass in a single harvest. Assuming the expression level of
CTB-PFx3 is around 3 mg ⁄ g of leaf tissue, and taking into consideration a 50% loss of protein during the purification process,
this could yield up to 20 million daily doses of insulin. However,
the efficiency of refolding would actually determine yield of
functional protein, and this has not been quantified in this
study. It is estimated that 220 million people worldwide have
diabetes, 10% of these having type 1 diabetes. Therefore, one
acre of biomass could produce enough insulin to treat a large
type 1 diabetic population, which would be a major economic
advantage.
There are many disadvantages to insulin injections which are
currently the most widespread form of administration. These
include, pain, itching, allergy and lipodystrophy at the injection
site. Additionally, these disadvantages often cause noncompliance of patients with their insulin regimen. Therefore, alterna-

tive approaches to insulin delivery are necessary to help diabetic
populations meet their medical needs. Some of the recent
approaches to address these problems include buccal spray
insulin, inhalable insulin, oral anti-diabetic drugs and oral delivery of insulin. Buccal spray insulin is absorbed by the mucosa of
the mouth and has a faster onset than injectable insulin. Limitations of this approach include a shorter duration of action and
a dosage requirement that is 5–7 times higher than injectable
insulin as well as mild side effects such as dizziness (Pozzilli
et al., 2010). Inhalable insulin faces similar challenges. The FDA
approved inhalable insulin, Exubera, was pulled off the market
because of poor sales and adverse side effects such as reduced
lung function (Siekmeier and Scheuch, 2008). Oral anti-diabetic
drugs are used mainly to treat type 2 diabetics as they improve
insulin production, so there is still a need to deliver functional
insulin to people with type 1 diabetes and type 2 diabetics who
require insulin. The main challenges that arise in advancing the
concept of oral delivery of insulin are protection from enzymatic
degradation in the stomach and efficient absorption into the
gut-associated lymphoid tissue (GALT, Agarwal and Khan,
2001). Approaches to overcome these challenges include
encapsulation of insulin using nanoparticles and the delivery of
insulin along with a protease inhibitor (Iyer et al., 2010). A
novel approach to circumvent these obstacles is the expression
of insulin in plant cells.
Insulin has never been produced without a fusion protein, as
it is highly unstable and is prone to N-terminal degradation
(Boothe et al., 2010). Therefore, we fused proinsulin with CTB
in order to protect the N-terminus of insulin from degradation
as well as provide a means to facilitate purification and uptake
of orally delivered insulin into the GALT. CTB binds to GM1
receptors in the lumen of the gut (Tsuji et al., 1995; de Haan
et al., 1998), and it has been shown that fusion to the C-terminus of CTB is ideal for pentamerization and GM1 binding (Liljeqvist et al., 1997; Limaye et al., 2006). Recently, CTB fused
with blood clotting factor IX was successfully expressed and
delivered orally to aid in treatment of haemophilia B. After
delivery, the antigen was found in different tissues of the GALT,
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specifically the ileum, Peyer’s patches, liver and plasma within
two hours (Verma et al., 2010). In order to successfully obtain
purified, functional insulin, the CTB-PFx3 must be solubilized in
high quantities of reducing agent. We achieved this by using
6 M GuHCl and 300 mM DTT. After solubilizing, it was necessary
to refold the denatured protein. This was achieved by dialysis in
20 mM sodium phosphate buffer containing 500 mM NaCl. The
refolded CTB-PFx3 was then run over the Ni2+ column. Proper
refolding was necessary in order to achieve purification because
the lack of a His-tag made it necessary to use the refolded CTB
moiety to bind to the Ni2+ column. CTB contains three histidine
residues that are in close enough proximity when properly
folded, which is enough to allow binding to anion exchange
resins such as Ni2+ or Co2+ (Dertzbaugh and Cox, 1998). This
way, purification of the CTB-PFx3 is facilitated by the CTB
fusion. Additionally, purification is enhanced by the fact that a
majority of the plant proteins are discarded with the supernatant, thus the initial sample to be purified contains only those
proteins that were insoluble, eliminating a majority of endogenous plant soluble proteins. When expressed in plants, the insulin is also protected from enzymatic degradation in the stomach
via bioencapsulation (Limaye et al., 2006; Davoodi-Semiromi
et al., 2010; Verma et al., 2010). Therefore, advancing the concept of oral delivery of insulin by expressing it in plant cells
should reduce its cost, facilitate purification and processing,
eliminate the need for cold storage and simplify transportation
and delivery (Daniell et al., 2009a).
Additionally, none of the alternative or currently used
approaches to insulin delivery include the C-peptide. C-peptide
is generally used as a marker to determine the extent of insulin
release in patients. A large portion of diabetic patients who
undergo extensive insulin therapy to maintain normal blood glucose levels still develop long-term complications such as neuropathy and nephropathy. C-peptide has been shown to alleviate
these complications in various studies, and this suggests that
diabetic patients should receive supplemental C-peptide in addition to insulin (Hills and Brunskill, 2009). For these reasons, we
have created cleavable proinsulin, which is able to be processed
into properly folded and functional insulin as shown by functionality studies in mice. Furin cleavage sites were chosen owing
to the fact that furin is an ubiquitous protease found in all
human cells and tissue types. We have worked with furin protease in previous animal studies involving oral tolerance, and no
adverse immunogenic effects have been seen (Verma et al.,
2010). Furthermore, furin cleavage has been used in several
studies to process human proinsulin to achieve safe and longterm expression (Suda et al., 2006). Upon cleavage, C-peptide
is available for circulation, where it may interact with its G-protein-coupled receptor and in turn activate the Na+ ⁄ K+ ATPase
and MAPK pathways, which are partly responsible for the beneficial effects seen in alleviating diabetic complications. This is
the first time that the complete proinsulin gene has been
expressed in plants with the possibility of in vivo processing outside the pancreas, into functional insulin and C-peptide.
Upon hyper-expression of cleavable proinsulin in tobacco and
lettuce chloroplasts, we noticed expression in the form of insoluble inclusion bodies similar to insulin inclusion bodies observed
in E. coli (Williams et al., 1982) or plants (Boothe et al., 2010).
The functionality of CTB stems from its ability to pentamerize in
order to bind to GM1 receptors (Liljeqvist et al., 1997) and has
been demonstrated to form functional pentamers in chloroplasts (Daniell et al., 2001; Limaye et al., 2006; Verma et al.,

2010). Additionally, insulin and proinsulin may form self-aggregates of monomers, dimers, tetramers and hexamers (Pekar and
Frank, 1972), which may further contribute to their aggregation
in chloroplasts. However, formation of pentamers, multimeric
forms and inclusion bodies caused the proinsulin to be highly
stable by conferring protection from proteases. The majority of
proinsulin accumulation was seen in older leaves as opposed to
mature leaves, which is often observed among foreign (soluble)
proteins expressed in chloroplasts (Tsuji et al., 1995; Koya et al.,
2005; Arlen et al., 2008; Daniell et al., 2009b). This may
account for the high levels of expression seen in old leaves, as
proinsulin may be protected from proteases (Martin and Thimann, 1972; Vierstra, 1993). Stability of CTB-PFx3 was even
seen in senescent and dried leaves that should facilitate harvest,
field drying, storage and transportation of this valuable protein.
This is the first report of stable accumulation of a therapeutic
protein in dried senescent leaves.
Attempts made to determine protein quantification by means
of enzyme-linked immunosorbent assay (ELISA) were unsuccessful because of the high quantity of protein aggregates, which
either inhibited binding to the ELISA plate or reduced the ability
of the CTB primary antibody from binding to the proper epitopes on the CTB molecule. Addition of DTT to the sample
extraction buffer or boiling of samples prior to coating of the
ELISA plate with CTB-PFx3 improved the detection of signal,
but not enough to yield an accurate quantification. The denaturation of the CTB-PFx3 monomer and multimers during the
immunoblot procedure most likely facilitated better binding of
the CTB primary antibody, allowing access to the desired epitopes. For densitometry studies, only the monomer and dimer
bands were used for the quantification, as the higher multimers
tended to form less defined bands. Therefore, the percentages
reported are likely an underestimation of the total expressed
CTB-proinsulin.
Mice that were given oral CTB-PFx3 experienced changes in
blood glucose levels, but levels were significantly lower at
120 min after the second dose when compared to mice given
untransformed lettuce. This demonstrates that proinsulin is
delivered to the circulation and is properly cleaved and folded.
In a recently published study, we observed blood clotting factor
IX fused with CTB in the circulatory system 2 h after oral delivery (the earliest time point in this study) of CTB-FIX expressed in
chloroplasts (Verma et al., 2010). Therefore, detection of plantderived insulin activity in less than two hours is quite reasonable. At this point, the percentage of orally delivered protein
absorbed by the GALT and delivered into the circulatory system
has not been fully investigated, although several bioencapsulated chloroplast-derived therapeutic proteins have been orally
delivered and shown to be fully functional. Additionally,
injected CTB-PFx3 must be processed into CTB and insulin when
compared with the commercial insulin, which is already in its
correct functional conformation. However, the efficiency of
refolding has not been quantified in our study. Therefore,
determining the actual amount of CTB-PFx3 mice received and
time required for processing would require further investigations. Future studies would investigate long-term effects of the
C-peptide delivery on diabetic complications in addition to the
effects of CTB-PFx3 on blood glucose levels. Although we investigated solubilization of multimers of proinsulin into monomers
for effective delivery of functional insulin, a recent study has
shown that injection of aggregates of insulin oligomers facilitates sustained and prolonged release, up to 140 days (Gupta
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et al., 2010). Therefore, further studies would investigate injection of chloroplast-derived oligomeric aggregates without solubilization into the monomeric form.

Experimental procedures
Vector construction
The CTB-PFx3 construct was created from pLD-5¢UTR-CTB-Pins as
previously described (Ruhlman et al., 2007). The proinsulin gene
was modified in order to include furin cleavage sites in between
the B-chain ⁄ C-peptide and the C-peptide ⁄ A-chain junctions as
well as between the CTB ⁄ B-chain fusion site. The pLD-5¢UTRCTB-Pins vector was digested with NcoI and SmaI, and the resulting portion containing the 5¢UTR was ligated into the pGEMPris(fx3) vector containing the mutated proinsulin. This was subsequently digested with EcoRI and NotI and subcloned into the
pLD-g10-RecA vector, replacing the g10-RecA gene with the
5¢Utr CTB-Pris(fx3) gene. The final vector was designated pLDutrCTB-Fx3Pris. To create the lettuce vector, pLDutr-CTB-Fx3Pris was
digested with SmaI and XbaI, and the resulting Fx3Pris fragment
was ligated into the 12.13.9.11 CTB-GPGP-FIX vector containing
the lettuce-specific psbA 3¢ and 5¢ UTRs, replacing the FIX gene.
To create the final vector, the pLspsbACTB-Fx3 Pris was digested
with NdeI and NotI and was cloned into pLsLFHPAG vector containing the lettuce flanking regions, and this vector was designated as pLsLF-CTB-Fx3Pris. After vector construction, the CTBPFx3 genes were sequenced (GENEWIZ). Sequences were confirmed to be correct using BLAST search.

Bombardment and selection
Bombardment was done using the Bio-Rad PDS-1000 ⁄ He gene
gun as described previously (Verma et al., 2008). Sterile tobacco
leaves were placed abaxial side up, whereas sterile lettuce
leaves were placed abaxial side down on Murashige and Skoog
(MS) medium and were bombarded under sterile conditions
using pLDutr-CTB-Fx3Pris or pLsLF-CTB-Fx3Pris coated with gold
particles prepared according to (Kumar and Daniell, 2004).
Bombarded leaf pieces were incubated in the dark for 2 days at
room temperature, and then leaf segments were transferred to
regeneration media of plants (RMOP) containing 500 mg ⁄ L
spectinomycin for tobacco or regeneration media of lettuce
(RMOL) containing 100 mg ⁄ L spectinomycin (Ruhlman et al.,
2010). The appearance of green shoots was seen after 4–
6 weeks. These shoots were allowed to grow, and the leaves
were cut and subsequently transferred to RMOP or RMOL containing 500 mg ⁄ L or 100 mg ⁄ L spectinomycin, respectively, for
the second round of selection. After new shoots formed, these
were transferred for the third round of selection to MS containing 500 mg ⁄ L spectinomycin for tobacco or 100 mg ⁄ L spectinomycin for lettuce and allowed to establish roots. Plants were
then transferred to the greenhouse.

Southern analysis to confirm homoplasmy
Transgenic and untransformed tobacco DNA was digested using
AflIII, and lettuce DNA was digested using BglII in a reaction
mixture containing 2 lL 10· buffer (New England Biolabs, Ipswich, MA), 3 lg plant genomic DNA, 2 lL BSA and 1 lL
enzyme made up to 20 lL with dH2O. The reactions were incubated overnight at 37 C. Southern analysis was performed
according to laboratory protocol (Kumar and Daniell, 2004).
The entire 20 lL restriction digestion samples were separated

on a 0.8% agarose gel at 50V for 4 h in Tris-acetic acid-EDTA
(TAE) buffer. The gel was depurinated for 15 min in 0.25N HCl,
rinsed two times for 5 min each in dH2O and soaked in transfer
buffer (0.4N NaOH, 1 M HCl) for 20 min. All steps were performed with gentle rocking. Capillary transfer was allowed to
take place over night. The next day, the membrane was rinsed
with 2· SSC (0.3 M NaCl, 0.03 M Sodium Citrate) two times for
5 min each, and DNA was cross-linked to the membrane at
150 mJ in GS Gene Linker (Bio-Rad, Hercules, CA). Flanking
sequence probe was generated by digesting the pUC-CT vector
(Verma et al., 2008) with BglII and BamHI in order to generate
a 0.81-kb fragment corresponding to the trnI ⁄ trnA region of
the native chloroplast genome. Probe was labelled with 32P
using Ready-to-Go DNA labelling beads (General Electric, Fairfield, MA). Hybridization was carried out using Stratagene
Quick-Hyb solution and protocol. Afterwards, the membrane
was placed in a cassette and exposed to X-ray film at )80 C.

Protein extraction and quantitation
Young, mature and old leaf tissue was ground to a fine powder
in liquid nitrogen using a mortar and pestle. Five hundred microlitres of plant extraction buffer (100 mM NaCl, 200 mM TrisHCl pH 8.0, 0.1% Triton-X, 400 mM sucrose, and Roche complete mini protease inhibitor cocktail tablet) was added to
100 mg of frozen leaf tissue and vortexed for 10 min at 4 C.
Plant tissue homogenates were further separated into supernatant and pellet fractions via centrifugation (20 000 g for 5 min
at 4 C), and the pellet was resuspended in 500 lL plant
extraction buffer for analysis. Total leaf protein concentration
was determined using the Bio-Rad protein assay dye reagent
concentrate. Dye was diluted 1 : 5 in water and filtered
through Whatman filter paper. The standard curve was made
using 0.4 mg ⁄ mL BSA serially diluted down to 0.006 mg ⁄ mL.
Plant homogenate, supernatant and pellet samples were diluted
in water 1 : 5, 1 : 10, 1 : 20 and 10 lL of sample, and BSA
standard was loaded in duplicate to a 96-well plate. Diluted
Bio-Rad dye (200 lL) was added to each sample and standard
and the plate was read on a plate reader at 595 nm.

SDS–PAGE and immunoblot analysis
Homogenate, supernatant and pellet samples were diluted in 2·
sample loading buffer (3.55 mL dH2O, 1.25 mL 0.5 M Tris-HCl
pH 6.8, 2.5 mL glycerol, 2 mL 10% SDS, 0.2 mL 0.5% bromophenol blue) and loaded onto a 12% SDS–PAGE (Bio-Rad) gel.
Samples were separated at 100–150V until the dye front reached
the bottom of the gel. After separation, the gel was either stained
with Coomassie Brilliant Blue R-250 (Bio-Rad) or transferred to a
nitrocellulose membrane (Bio-Rad) for immunoblot analysis.
Transfer was carried out using a Bio-Rad transfer cassette at 85V
for 1 h. Membranes were briefly rinsed in dH2O and blocked in
PBS-Tween-20 + 3% dry milk (PTM) for 30 min to 1 h. CTB-PFx3
was detected using anti-CTB primary antibody (Sigma, St. Louis,
MO) diluted 1 : 4000 for 1.5 h followed by goat anti-rabbit IgGHRP (Southern Biotech, Birmingham, AL) at a dilution of 1 : 5000
for 1 h. Proteins were subsequently detected on autoradiography
film using SuperSignal West Pico Chemiluminescent Substrate
(Thermo Scientific, Waltham, MA).

Densitometric quantification of CTB-proinsulin
Immunoblots for quantification were performed using known
concentrations of CTB protein standard (Sigma) of 25, 50, 100,
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200 and 400 ng in order to create a standard curve. Total protein concentration was determined via the Bradford assay (BioRad). Varying concentrations of CTB-PFx3 plant homogenate
were directly compared to the standard curve using Alphaimager and Alphaease FC software. The percentage of CTB-PFx3 relative to the concentration of total leaf protein and mg CTBPFx3 per gram leaf tissue were calculated according to the formula published in (Verma et al., 2008).

Protein solubilization and furin cleavage
CTB-PFx3 homogenate was separated into supernatant and pellet fractions. The pellet fraction containing the CTB-PFx3 in an
insoluble form was resuspended in 1.5 mL of plant extraction
buffer per 100 mg ground plant tissue along with 100–300 mM
dithiothreitol (DTT, Promega Fitchburg, WI) and 6 M guanidine
hydrochloride (Gu-HCl, Sigma). Samples were rocked for 16–
18 h at 4 C. The samples were then centrifuged at
14 000 rpm for 5 min at 4 C, and the supernatant containing
soluble CTB-PFx3 was separated from the pellet fraction. The
samples were subsequently dialysed using Spectra ⁄ Por molecularporous membrane tubing (Fisher Scientific, Waltham, MA) in
20 mM sodium phosphate pH 7.8, 500 mM NaCl overnight at
4 C. For cleavage with furin protease, 1 lg of dialysed sample
was incubated with 100 mM HEPES pH 7.5, 0.5% Triton X-100,
1 mM CaCl2, 1 mM 2-mercaptoethanol, and 2 units furin (New
England Biolabs) at 25 C for 16 h.

Affinity purification
After solubilization and dialysis of the CTB-PFx3, the resulting
supernatant was passed over a column (Clontech, Mountain
View, CA) consisting of 2 mL Ni-NTA Agarose (Qiagen, Venlo,
the Netherlands) which was equilibrated with 20 mM sodium
phosphate pH 7.8 and 500 mM NaCl (Binding buffer). The column was subsequently washed with 30 mL binding buffer and
then with 30 mL wash buffer (20 mM sodium phosphate pH 6.0
and 500 mM NaCl). Samples were eluted from the column in
1 mL fractions using 10 mL elution buffer (20 mM sodium phosphate pH 6.0, 500 mM NaCl, and 250 mM imidazole). All steps
were carried out at a flow rate of 0.5 mL ⁄ min. Fractions were
assayed for protein concentration via absorbance units at
280 nm using the SmartSpec 3000 (Biorad) and Bradford assay
to determine the concentration in mg ⁄ mL. Purified CTB-PFx3
(1 lg) was incubated with furin, and cut and uncut samples
were run on a 16% Tricine-SDS gel. Samples were also subsequently run on 12% SDS–PAGE gel and subjected to coomassie
stain and immunoblot in order to determine the per cent purity.

solution (20 mg Na2S2O3 in 100 mL dH2O) for exactly 1 min
and then washed in dH2O 3· for 5 min each. Silver solution
(200 mg AgNO3 and 100 lL formaldehyde in 100 mL dH2O)
was added and the gel was rocked for 30 min. The gel was
washed in dH2O 4· for 5 min each and then developer solution
(6 g Na2CO3, 100 lL of hypo, 100 lL formaldehyde in 300 mL
dH2O) was added. The gel was vigorously shaken in developer
solution until protein bands appeared, and then the reaction
was stopped by addition of 5% acetic acid.

Animal studies to determine functionality
All procedures performed in this study are based on an
approved protocol in accordance with UCF-IACUC. Female
C57BL ⁄ 6 mice weighing 17–20 g each were purchased from
the Jackson Laboratories (Bar Harbor, ME). Mice were divided
into four groups with six mice per group. Samples were prepared for delivery via IP injection by dilution in sterile PBS. Commercially purified insulin and purified CTB-PFx3 derived from
transgenic tobacco were normalized via immunoblot and subsequently diluted to give each mouse a dosage of 0.04 U ⁄ kg of
commercially prepared insulin (Roche) and 8 lg ⁄ mouse of
plant-derived purified CTB-PFx3. IP injections were delivered in a
volume of 100 lL. Blood glucose levels were measured by
bleeding of the tail vein before sample administration and again
at 15, 30, 60, 120 and 180 min after sample administration
(Accu-Chek, Aviva; Roche, Basel, Switzerland). A second injection was given after 180 min, and blood glucose measurements
were taken at 15, 30, 60, 120 and 180 min after the second IP
injection. Food pellets were removed for the duration of the
study. For the oral study, female C57BL ⁄ 6 mice were divided
into four groups with five mice per group. Commercially purified insulin was diluted in sterile PBS and given at a dose of
0.04 U ⁄ kg. IP injections were delivered in a volume of 100 lL.
Oral samples were prepared from material ground in liquid
nitrogen and stored at )80 C until the day of the experiment.
Prior to gavage, 3 g of wild-type and transgenic leaf material
were mixed with 500 lL 20· PBS and homogenized using a
General Laboratory Homogenizer (GLH-2596, Omni International, Kennesaw, GA) for 5 min. Two hundred microlitres
(200 mg) of leaf material containing approximately 0.5 mg
CTB-PFx3 was administered orally to mice via a 20-gauge
gavage needle. Blood serum was taken by bleeding of the tail
vein before sample administration and again at 15, 30, 60, 120
and 180 min after sample administration. A second dose was
given after 180 min, and blood glucose measurements were
taken at 15, 30, 60 and 120 min after the second dose.

Sodium phytate precipitation
Sodium phytate precipitation was performed to remove Rubisco
from purified samples. Purified samples were treated with
10 mM CaCl2 and 10 mM sodium phytate (phytic acid sodium
salt hydrate from Sigma) for 10 min at 37 C. Afterwards, samples were spun in a tabletop centrifuge at room temperature
for 10 min at 14 000 rpm. Supernatant was removed, placed in
a fresh tube and stored at )20 C until use.

Silver stain
Tricine-SDS gel was incubated in fixative (45% dH2O, 45%
methanol, 10% acetic acid) for 40 min. The gel was then
washed with 50% methanol 2· for 5 min each and then with
dH2O 2· for 5 min each. Next, the gel was rocked in Hypo
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